Opinion|Videos|May 13, 2024
Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.
Advertisement
Episodes in this series
What is amyloid precursor protein (APP)? How are amyloid β (Aβ) peptides, Aβ42 and Aβ40, generated?
Which soluble or insoluble species of Aβ (monomers, oligomers, protofibrils or amyloid plaques) contribute to neuronal damage and clinical manifestation of Alzheimer’s disease?
Advertisement
Related to this article
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
Subgroup analyses from the phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, malaise, and cognition in long COVID patients with more severe baseline symptoms.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
3
RIPK1 Inhibitor Fails to Slow Functional Decline in Phase 2 ALS Trial
4
Previewing Advancements in Hypersomnia Diagnosis and Treatment
5